相似文献
1
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.
Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.
2
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
3
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation.
Future Oncol. 2021 Jan;17(2):215-227. doi: 10.2217/fon-2020-0700. Epub 2020 Sep 25.
4
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27.
5
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.
6
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
7
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Rinsho Ketsueki. 2020;61(4):322-326. doi: 10.11406/rinketsu.61.322.
8
Availability of FLT3 inhibitors: how do we use them?
Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26.
9
Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Target Oncol. 2020 Oct;15(5):681-689. doi: 10.1007/s11523-020-00749-3.
10
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Oncologist. 2021 Feb;26 Suppl 1(Suppl 1):S10. doi: 10.1002/onco.13652. Epub 2020 Dec 24.
引用本文的文献
1
RNA activation of improves leukemia treatment.
Mol Ther Nucleic Acids. 2025 Jun 16;36(3):102611. doi: 10.1016/j.omtn.2025.102611. eCollection 2025 Sep 9.
2
Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment.
Cancers (Basel). 2024 Dec 11;16(24):4136. doi: 10.3390/cancers16244136.
3
Cholesterol inhibition enhances antitumor response of gilteritinib in lung cancer cells.
Cell Death Dis. 2024 Sep 30;15(9):704. doi: 10.1038/s41419-024-07082-x.
4
How I treat acute myeloid leukemia with differentiation therapy.
Blood. 2025 Mar 20;145(12):1251-1259. doi: 10.1182/blood.2024024008.
5
Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies.
Int J Mol Sci. 2024 Jun 8;25(12):6356. doi: 10.3390/ijms25126356.
6
Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.
Cancers (Basel). 2024 Jan 29;16(3):569. doi: 10.3390/cancers16030569.
7
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Leukemia. 2024 Feb;38(2):291-301. doi: 10.1038/s41375-023-02131-4. Epub 2024 Jan 5.
8
Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia.
Front Pharmacol. 2023 Oct 26;14:1258151. doi: 10.3389/fphar.2023.1258151. eCollection 2023.
9
Differentiation Syndrome in Acute Leukemia: APL and Beyond.
Cancers (Basel). 2023 Sep 28;15(19):4767. doi: 10.3390/cancers15194767.
10
Evaluation of hypereosinophilia in a case of -mutant acute myeloid leukemia treated with gilteritinib.
Cold Spring Harb Mol Case Stud. 2023 Jul 11;9(3). doi: 10.1101/mcs.a006279. Print 2023 Jun.
本文引用的文献
1
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.
Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.
2
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
3
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
4
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations.
Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.
5
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
6
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
7
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.
8
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1.
9
FLT3 Inhibitor-Associated Neutrophilic Dermatoses.
JAMA Dermatol. 2016 Apr;152(4):480-2. doi: 10.1001/jamadermatol.2015.6121.
10
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20.
Zotero 插件